Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$340.47M+1329.83%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph K. Belanoff
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 730
- Beta
- 0.45
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 23.68
Financials
Revenue
$340.47M+1329.8%Net Income
$126.78M+2657.8%EBITDA
$121.33M+2316.0%Free Cash Flow
$142.18M+3063.8%EPS (diluted)
$1.01+2381.6%Shares Outstanding (diluted)
123.20M+9.2%Operating Expenses
$221.14MCash & Debt
$370.70MReturn of Capital
$5.75MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $761.41M | $99.65M | $0.95 |
| 2024 | $675.04M | $139.73M | $1.35 |
| 2023 | $482.38M | $106.14M | $1.02 |
| 2022 | $401.86M | $101.42M | $0.95 |
| 2021 | $365.98M | $112.51M | $0.97 |
| 2020 | $353.87M | $106.01M | $0.92 |
| 2019 | $306.49M | $94.18M | $0.82 |
| 2018 | $251.25M | $75.41M | $0.60 |
| 2017 | $159.20M | $129.12M | $1.14 |
| 2016 | $81.32M | $8.14M | $0.07 |
| 2015 | $50.29M | $-6.41M | $-0.06 |
| 2014 | $26.55M | $-31.38M | $-0.31 |
| 2013 | $10.36M | $-46.01M | $-0.46 |
| 2012 | $3.31M | $-38.05M | $-0.41 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.41
- Implied price
- $52.16
- Return from $63.62
- -3.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $25.93 — -59.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 31 | 37 | 43 | 49 |
|---|---|---|---|---|---|
| -2.0% | -19.4% | -15.8% | -12.8% | -10.1% | -7.8% |
| 3.0% | -15.3% | -11.5% | -8.3% | -5.5% | -3.0% |
| 8.0% | -11.1% | -7.2% | -3.9% | -1.0% | 1.7% |
| 13.0% | -7.0% | -2.9% | 0.6% | 3.6% | 6.4% |
| 18.0% | -2.9% | 1.4% | 5.0% | 8.2% | 11.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
163+226.67%Social Signal Score
Mentions (20)
- News (RSS)seekingalpha·2d ago·Positive
Corcept Therapeutics: Strong Lifyorli Sales Can't Hide A Looming Competitive Cliff
View source ↗ - News (RSS)seekingalpha·2d ago·Neutral
Corcept Therapeutics: Two Franchises, But One Broader Cortisol Opportunity
View source ↗ - Newsseekingalpha.com·2d ago·Positive
Corcept Therapeutics: Two Franchises, But One Broader Cortisol Opportunity I rate Corcept Therapeutics Incorporated Buy with an $82 target; growth opportunities appear underappreciated, and my base case does not require Cushing's approval. CORT Q3 revenue rose 64% to $340.5 million as Korlym grew despite generic competition and Lifyorli gained traction. The December 17 FDA decision and Teva litigation could drive significant volatility; I would size positions cautiously.
View source ↗ - Newszacks.com·18d ago·Positive
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Corcept targets $3B-$5B in Cushing’s revenue in 2030 as it awaits December 17 relacorilant FDA decision
View source ↗ - News (RSS)seekingalpha·18d ago·Positive
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
Corcept Therapeutics Q3 Earnings Call Highlights Corcept Therapeutics NASDAQ: CORT reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results.
View source ↗ - Newszacks.com·19d ago·Positive
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates Corcept Therapeutics (CORT) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.16 per share a year ago.
View source ↗ - News (RSS)investing·27d ago·Positive
Why is Corcept Therapeutics stock rallying today?
View source ↗ - Newszacks.com·34d ago·Negative
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
View source ↗ - Newsdefenseworld.net·34d ago·Negative
Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in Stock Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) Director James Wilson sold 10,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $114.81, for a total value of $1,148,100.00. Following the completion of the sale, the director directly owned 1,054,543 shares of the
View source ↗ - News (RSS)investing·54d ago·Positive
Corcept Therapeutics options: a long strangle signals volatility bet ahead of 2027
View source ↗ - Newszacks.com·67d ago·Positive
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
View source ↗ - Newsfxempire.com·67d ago·Positive
Corcept Grows to Mid-Cap on Institutional Support Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.
View source ↗ - News (Marketaux)seekingalpha.com·75d ago·Positive
Corcept Stock: Not Cheap, But Backed By Real Structural Growth (NASDAQ:CORT) The way I see it, Corcept T[+141 characters]
View source ↗ - Newszacks.com·86d ago·Neutral
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report? Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)seekingalpha·93d ago·Neutral
Like The Knick's, Corcept Rebounded And Is Crushing It
View source ↗ - Newsseekingalpha.com·93d ago·Positive
Like The Knick's, Corcept Rebounded And Is Crushing It Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.
View source ↗ - Newsfinbold.com·96d ago·Neutral
Trump is up 230% on this stock trade since March President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $1.12 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$1.01 vs $0.84beat
- Wed, Jul 29$0.36 vs $0.02beat
- Thu, Apr 30$-0.30 vs $-0.11miss
- Tue, Feb 24$0.20 vs $0.33miss
- Tue, Nov 4$0.16 vs $0.18miss
- Thu, Jul 31$0.29 vs $0.23beat
Estimates and results for CORT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CORT officers and directors.
- Bought
- —
- Sold
- $21.3m
0 trades
38 trades
- Wilson James Nsold
- Wilson James Nsold
- Wilson James Nsold
- Wilson James Nsold
- Swisher Daniel N Jrsold
- Maduck Seansold
- Maduck Seansold
- Maduck Seansold
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CORT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
